UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield investment to establish a manufacturing presence in Singapore with the construction of a state-of-the-art antibody-drug conjugate (ADC) production site. This facility will be the company’s first end-to-end manufacturing hub, handling all stages of ADC production, including antibody production, warhead and linker synthesis, conjugation, and filling.
The construction of this strategic project is set to commence in 2023, with operations expected to begin in 2029. This expansion is aimed at bolstering the global supply chain for AstraZeneca’s portfolio, which includes six wholly owned ADCs currently in clinical development.- Flcube.com
